The Cannabinoid THCV May Treat Acne

Cannabis is a treasure trove of medicines. The plant’s 80+ cannabinoids offer treatment and relief from a long list of maladies: acne may now be included. The cannabinoid TCHV may offer a powerful treatment for acne, according to new European research.

Acne is an inflammation of the sebaceous glands, often on the faces of teenagers.    The gland’s duct can become blocked, perhaps from excess sebum produced by teenage hormones. Blocked glands can suffer bacterial infection, producing the common, if distressing, lesions on the skin.

Earlier, this same group found potential for the cannabinoid CBD (cannabidiol) in acne treatment.  Published in the Journal of Clinical Investigation, they concluded,

Collectively, our findings suggest that, due to the combined lipostatic, antiproliferative, and antiinflammatory effects, CBD has potential as a promising therapeutic agent for the treatment of acne vulgaris.”

The researchers followed up by studying five other cannabinoids as possible treatment of acne and related skin conditions. THCV, (-)-Δ9 -tetrahydrocannabivarin, CBC, CBDV, CBGV and CBD. They found different effects: CBG and CBGV may help in the treatment of dry skin. Concerning the opposite problem, excess lipogenesis and acne, the researchers found that:

CBC, CBDV and especially THCV show promise to become highly efficient, novel anti-acne agents. Moreover, based on their remarkable anti-inflammatory actions, phytocannabinoids could be efficient, yet safe novel tools in the management of cutaneous inflammations.

Cannabinoid Receptors Help Reduce Parkinson’s Disease (PD) Inflammation

Our body’s natural cannabinoid receptors may play an important role in reducing inflammation in Parkinson’s Disease (PD).

Parkinson's disease patient showing a flexed w...

Parkinson’s disease patient showing a flexed walking posture pictured in 1892. Photo appeared in Nouvelle Iconographie de la Salpètrière, vol. 5. (Photo credit: Wikipedia)

Once again, ground breaking cannabinoid research is announced by researchers at Madrid’s Complutense University. Chronic inflammation anywhere in our bodies is a destructive process; in the brain it is particularly insidious. “Inflammation is an important pathogenic factor in Parkinson’s disease (PD),” remind the Spanish researchers in this new study. Inflammation can “kill dopaminergic neurons of the substantia nigra and to enhance the dopaminergic denervation of the striatum.”

Among the many functions of your endocannabinoid system is control of inflammation., and more generally, protecting nerve cells (neuroprotection). Your cannabinoid system activates from interaction with your natural endocannabinoids such as anandamide. Plant cannabinoids such as THC and CBD, and synthesized research cannabinoids can also modulate your endocannabinoid system, through its receptors CB1 and CB2, (and other receptors and processes).

This new Spanish research focused on receptor CB2.

Unlike CB1 receptors which are found primarily in the outer layer of neurons in the brain and throughout the body, CB2 receptors are more associated with the immune system. This research looked at CB2 in brain cells, not in neurons, but in microglia support cells. About one out of seven of your total brain cells are these microglia immune cells; macrophage-like, they serve as a sensitive as house-keepers, removing damaged neurons and other waste material. When need be, microglial cells mount a powerful protective force against bacterial and other threats to your neurons.

The Spaniards write:

The cannabinoid type-2 (CB2) receptor has been investigated as a potential anti-inflammatory and neuroprotective target in different neurodegenerative disorders, but still limited evidence has been collected in PD. Here, we show for the first time that CB2 receptors are elevated in microglial cells recruited and activated at lesioned sites in the substantia nigra of PD patients compared to control subjects.

In an earlier study, some of the same researchers examined the possible use of the cannabinoid THCV (tetrahydrocannabivarin) . See Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson’s disease. Again, activation of CB2 receptors was the focus. The researchers concluded:

Given its antioxidant properties and its ability to activate CB(2) but to block CB(1) receptors, Δ(9)-THCV has a promising pharmacological profile for delaying disease progression in PD and also for ameliorating parkinsonian symptoms.

Cannabis Oil: A Medical Marvel For Your Skin?

Back massageAs medical and personal use of marijuana become increasingly legal, many new ways to intake cannabis are now available. In addition to inhaling smoke, people can benefit from the medical cannabinoids in cannabis by vaporizing, ingesting, and absorption via the skin.

Plant cannabinoids, such as THC and CBD,  are fat soluble and readily absorbed by the skin. These medicinal molecules may well be most perfectly administered, for many conditions, via topical products applied directly to the skin’s surface, such as cannabis-infused massage oil. To clarify, this is not “hemp oil” from the seeds of low cannabinoid hemp, but made from the flowers (buds) themselves, and filled with cannabinoids.

© freshidea - Fotolia.com

© freshidea – Fotolia.com

The importance of the endocannabinoid system (ECS) to the healthy functioning of the skin is only now becoming clear, as the profound ways the ECS effects all our systems are continually discovered. This system,with natural receptors (CB1 and CB2) found in brain, immune and most types of cells, including those in the skin, and natural endocannabinoids our bodies produce, are perhaps the greatest discoveries in human physiology of the last 50 years.

During these same time, researchers discovered the ability for plant based cannabinoids from cannabis, including THC and  CBD, to activate the ECS.  These cannabinoids offer great potential for preventing, treating, and curing common skin diseases. Massages using cannabis infused oil may be an optimal way to address skin maladies. Cannabinoids may be very useful in treating skin cancer.

The endocannabinoid anandamide (AEA) has been found to play a key role in the health of the skin, prompting these Italian researchers to study cannabinoids cannabidiol (CBD), cannabigerol (CBG), and  cannabidivarin (CBDV) to study effects on skin cells. The Italian study skipped THC because of its psychoactivity, but THC has been shown to be powerfully therapeutic. THC is actually closer to AEA in function than is CBD, so it would have been interesting if it were included in the study.

Many skin conditions are inflammatory in nature and the anti-inflammatory effects of cannabinoids on skin cells have been demonstrated. Both THC and CBD show anti-inflammatory effects.

Cannabinoids also act on the genetic level to help calm skin diseases. The field of Epigenetics studies how “molecular mechanisms in the environment control gene activity independently of DNA sequence.” Activities such as exercise and factors such as nutrition and stress can change how genes are expressed. Endocannabinoids made by your own cells and phytocannabiniods from cannabis sativa also can change genetic expression in medically useful ways, addressing diseases from psoriasis to cancer.

The report concluded: “These findings show that the phytocannabinoids cannabidiol and cannabigerol are transcriptional repressors that can control cell proliferation and differentiation. This indicates that they (especially cannabidiol) have the potential to be lead compounds for the development of novel therapeutics for skin diseases.”

THC infused oils may offer many benefits missing from potions without this main cannabinoid. One of these benefits might be the “psychoactivity” seemingly dreaded by cannabinoid researchers. Patients may well enjoy the blissful experience, and even consider it part of the cure.

Watch for Part 2 of this series for more on the science, on the new found epigenetic capabilities of cannabinoids, how marijuana’s amazing molecules adjust gene expression to protect skin.

Football Concussions and the Brain-Saving Effects of Cannabis

© intheskies - Fotolia.com

© intheskies – Fotolia.com

The prevalence of brain injuries associated with football are becoming increasingly clear. More than anyone suspected, banging heads together in football causes mild (and not so mild) traumatic brain injuries( mTBI). New findings and the plights of many former players may fundamentally change the game of American football, from the NFL all the way down through college and high school to Pop Warner. The latter kid’s league is suffers declining participation as parents fear damage to their children’s brains.

During the same time period that the the severity of brain-damaging injuries suffered by football players was becoming clear, research in Israel and Spain began to show that the human brain is protected from TBI by the cannabinoids in cannabis.

It may well turn out to be that the best on-field treatment of a suspected concussion will be taking “hits” of vaporized cannabinoids, right from medical cannabis. Even now, portable vaporizers can be ready to provide a controlled dosage of cannabinoids within a few seconds.

At the same time, new helmets with  accelerometers for measuring impact force and gyrometers for measuring twist will help in the immediate assessment of possible concussion after a violent tackle or block. Perhaps LED lights will read out G force readings right on the helmet’s surface, allowing fellow players, coach, and trainer to spot potential dangers.

Imagine this scenario in the not-too-far future: At a home game in Seattle or Denver or other state with medical marijuana exemption to tyrannical federal marijuana laws, the home team quarterback sets his squad on a crucial third down. Unfortunately for him, he was swallowed in a pass rush; worse yet when he was floored by a 300 pound left tackle, his helmet smashed into that of another tackler at a high rate of force. He lay stunned, not quite sure why to get up. Coach and team physician approach at a jog alarmed to see the red glow from the helmet LED declaring a probably concussion. As the physician reads the G force readings from the collision, she clicks on the portable vaporizer. She asks the player a few questions, at which he performs badly. He can state his name but is unsure of the date, even the year. This, along with the red light concussion warning and the dangerously high deceleration ‘G’ rating, convinces her to act immediately, bringing the vaporizer to the injured player’s lips and telling him, “breathe in this medicine.”

As the brain-traumatized player inhales cannabinoids into his lungs, they quickly make it to his heart and fountain up to his brain. Within seconds the cannabinoids THC, CBD and others cross the blood-brain-barrier in his brain and begin their neuroprotective functions. In the injured brain, neurotransmitters, particularly glutamate, are overproduced in a frenzy that damages neurons. Inflammatory processes produce reactive oxygen species (ROS), dangling electrons that wound cell walls and DNA. In this unlikely scenario, total time from traumatic brain injury, to diagnosis, to treatment molecules reaching the site of injury was perhaps one minute. This may also be a future protocol in case of stroke, another source of traumatic brain injury.

In the brain these cannabinoids dampen down the frenzied, brain-damaging transmitters. Cannabinoids, including THC and CBD, reduce production of the transmitter glutamate. Cannabinoids also serve as antioxidants to sop up the dangerous ROS oxidants. They calm the brain and reduce inflammation.

In moves it looks like the NFL might actually do, the league should end any restriction for players using cannabis. Not only is it good for their battered brains but also offers the safest medication for several types of pain, including neuropathic pain. There is actually more justification for making cannabis use by NFL players mandatory than there good reasons for its prohibition. Strict enforcement of rules penalizing wounding play actions such as ‘helmeting’ will also help.

Medical Cannabis Refugees

Americans in dire need of medical cannabis for themselves or their children are being forced to flee to states with humane laws providing access to their medicine. For many people and especially parents, access to medical marijuana is literally a matter of life and death.  marijuana and pillsMost US states still adhere to draconian laws regarding any possession of cannabis and afford medical users no protection. Parents face prosecution, even loss of possession of their children for trying to supply them natural compounds that can save their children’s lives from slow death by seizures, sometimes hundreds a day.

Ironically, the main compound sought by these parents is the CBD or cannabidiol. Unlike psychoactive cannabinoid THC, CBD provides no ‘high,’ the mental state seemingly so feared by nearly all researchers. Nevertheless, CBD is itself classified, as are all cannabinoids from marijuana, as a Schedule I drug, highly dangerous and without medical value. This for a compound with no psychoactivity, nor toxicity that may well turn out to be one of the most significant medicines ever discovered. This is your government on drugs.

Certainly to a growing group of parents and stricken children in states like Colorado, CBD is a momentous medical godsend. As reported by CNN’s Sanjay Gupta in his documentary Weed, CBD strains of medical marijuana provide blessed relief from childhood seizures and developmental problems caused by Severe Myoclonic Epilepsy of Infancy (SMEI), aka Dravet Syndrome. Where mixtures of powerful and dangerous pharmaceutical drugs of every type had failed to stop the seizures, and almost killed their small patients, CBD tinctures provided immediate relief.

Seeing such dramatic improvement for such a heart-breaking condition, parents of children with similar conditions across the country of course became excited about the possibility of providing their infants with relief. But because medical cannabis research has been blocked by the DEA and Schedule I status, these new high-CBD medicines are in short supply, available (and legal) pretty much only in Colorado.

The situation is leading to a medical cannabis refugee movement from states with harsh and cruel laws to states where voter’s have mandated legal exemption for medical use, like Colorado, Washington, Oregon and California. The first two states on this list also now allow personal use of cannabis, again voted in by the citizens of Colorado and Washington.

An excellent series in the Salt Lake Tribune documents this process of “Families migrating to Colorado for a medical marijuana miracle.” The article’s author, Kirsten Stewart interviews physician Dr. Margaret Gebbe, who calls the results of CBD in treating these epilepsy disorders as “absolutely remarkable.” Dr. Gebbe is also interviewed by Dr. Sanjay Gupta in his Weed documentary.

Sanjay Gupta reports on a similar movement on an international scale, with his story on a British citizen traveling to the Netherlands for access to his preferred pain treatment, cannabis sativa. He shows Gupta vial after vial of pharmaceutical narcotics he has been prescribed but were ineffective and with mind numbing side effects. Treatment with cannabis is unavailable in England, making this middle age man, bedeviled by pain cross the channel as another medical cannabis refugee.

American states and world countries that recognize the idiocy of cannabis prohibition and the powerful medical potential of cannabis will prosper while providing hugely needed relief and succor to these refugees.

Copyright © 2013 by Don Fitch

Cannabinoid Receptors and Pain Relief with Acupuncture

Acupuncture has long been shown to relieve pain, but medical science lacked a mechanism to explain how it works. Now research out of Shanghai China reported in Evidence-Based Complementary and  Alternative Medicine finds that the cannabinoid system provides an answer.

The new research is entitled Electroacupuncture inhibition of hyperalgesia in rats with adjuvant arthritis: involvement of cannabinoid receptor 1 and dopamine receptor subtypes in striatum. The cannabinoid system is the regulatory system discovered and revealed over the past 25 years to play major roles in homeostasis and pain relief.  The cannabinoid receptor 1 mentioned is usually abbreviated CB1, and is the main receptor activated by cannabis (marijuana) and also by natural endocannabinoids produced by our bodies.

Based on their knowledge that dopamine D1/D2 receptors are involved in electroacupuncture analgesia, they conjectured that the  ” CB1 and dopamine systems sometimes interact and may operate synergistically in rat striatum.”  They found at the sites of two pain relieving acupuncture points “that the levels of CB1 expression in the repeated-EA group were much higher.”  They conclude, “these results suggested that the strong activation of the CB1 receptor after repeated EA resulted in the concomitant phenomenon of the upregulation of D1 and D2 levels of gene expression.” Activating these CB1 receptors turned on the D1/D2 receptor genes.

The authors conjectured, “One unproved but intriguing idea is that endocannabinoids may set the analgesic tone of the

© StockHouse - Fotolia.com

© StockHouse – Fotolia.com

body, with the level of their production acting as a kind of pain thermostat.” Again, the cannabinoid receptor system shows its huge importance in human physiology. Electroacupuncture and cannabis both activate the CB1 receptor and both result in pain relief.

Your Brain on CBD: Neurogenesis and Brain Growth!

Neurogenesis in hippocampus

© Sebastian Kaulitzki – Fotolia.com

We rightfully mourn the loss of brain cells, neurons, as we age. As they die we lose memories and capabilities – even our personalities. We are only as robust as our brains, composed mainly of neurons. Formerly, it was thought the as adults we already have all the brain cells we will ever have, and the path was only downward as we lose neurons to stress, alcohol and aging. Happily, this bleak picture was changed when neuroscientists discovered that, under certain conditions, even adult brains can grow new neurons, neurogenesis. New neurons refresh and rejuvenate, and lift mood.

The principal area where neurogenesis can take place is in the hippocampus, a dual area deep within the brain. Although small, hippocampal health appears important to memory and brain organization. It can be damaged. Excess alcohol and many drugs can cause it to lose neurons and shrink, resulting in fading memories and depression.

On the other hand, several conditions seem to spur brain growth. Physical exercise is one: rigorous physical activity spurs the growth of new neurons in the hippocampus, most probably providing a rejuvenating effect and boosting memory. Physical activity is crucial in keeping old brains young. Your hippocampal health is one of dozens of great reasons to exercise every day of your life.

Certain anti-depressant drugs are also associated with neurogenesis.  Indeed, it is now thought that the depression relieving effects of SRIs- serotonin reuptake inhibitors – might have more to do with neurogenesis than increasing serotonin levels. Some now believe that the depression lifting effects of these drugs are due to new, young brain cells refreshing the hippocampus.

In 1995 it was reported that cannabinoids, too, can spur neurogenesis. Cannabinoids are molecules from three different sources: 1) Our body produces endocannabinoids that activate our endocannabinoid regulatory systems, pricipally anandamide and 2-AG. 2) Phytocannabinoids come from the plant Cannabis Sativa, AKA marijuana. THC is the best known and produces the psychoactive and some of the medicinal effects of cannabis.  3) Cannabinoids can also be synthesized in the lab.

A Canadian research group reported that Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. This research used a synthetic cannabinoid to activate the same CB1 receptors activated by the plant cannabinoid THC. They attributed the anxiety-relieving and depression-lifting effects of long-term treatment were “likely via promotion of hippocampal neurogenesis.”

Another new study has shown that the cannabinoid CBD from cannabis also promotes neurogenesis. Researchers from the Complutense University in Madrid, along with Brazilian researchers found that CBD relieved stress in mice and it did so by increasing neurogenesis in the hippocampus. They concluded, the “anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.”

CBD, Cannabidiol is an exceedingly interesting molecule, brimming with beneficial health effects. It is one of over 60 cannabinoids produced by the hemp plant Cannabis Sativa. Unlike the better known THC, CBD is not psychoactive, although it may modulate the effects of THC. Both cannabinoid molecules interact, in different ways, with our cannabinoid receptors CB1 and CB2. The medical potential of CBD has been inadequately studied because of the idiotic illegality of Cannabis Sativa. Even so, the known health effects are impressive: Like THC, CBD is an antioxidant with neuroprotective properties. Like THC, CBD is anti-inflammatory. It relieves pain.  CBD appears to have anti-tumor properties.

So on top of all these medical benefits, CBD may well contribute to neurogenesis, brain rejuvenation and growth! What’s not to like? Well, the DEA does not like these medical benefits and does not allow research on them because it likes the draconian Schedule I – no medical benefits – of cannabis to extend the lucrative war on drugs. This bureaucratic turf battle keeps the DEA in the dough but denies Americans the health-giving, even life-saving benefits of medical cannabis, even non-psychoactive CBD-dominant strains.

Americans should demand access to natural plant molecules such as CBD, along with THC, THCV and dozens of other medical cannabinoids. CBD and these other cannabinoids can help prevent many maladies, can treat dozens of diseases and can provide palliative comfort to the rest.  Along with refreshing and growing our very brains with neurogenesis. If Americans gain their medical freedom with a down-grading of cannabis from ridiculous Schedule I tyranny, the planet’s other six billion people would also gain greater access. Study of this remarkable  plant cannabinoid would blossom world-wide as anti-cannabis doctrine crumbles in the face of huge medical and health benefits.

Copyright © 2013 Don Fitch

THCV: A Marijuana Cannabinoid for Weight Loss and Diabetes Prevention?

Fotolia

Fotolia

The cannabis sativa plant, marijuana, produces dozens of cannabinoids. The THC cannabinoid that elicits psychoactivity, and numerous medical benefits, is but one of over 60 phyto (plant-based) cannabinoids found in cannabis. Cannabidiol or CBD, is a second, now under intense study for its anti-inflammatory and other health properties. Another of these phytocannabinoids is  tetrahydrocannabivarin or THCV. Cannabis strains favoring this cannabinoid might serve as tools for weight loss and preventing diabetes.

Medical research on cannabinoids has flourished in recent years and most research points to health positive effects of medical cannabis for a wide range of conditions. Cannabis has been found to be neuroprotective, anti-painantioxidant, antiseptic, anti-inflammatoryanti-tumor as well as cardioprotective. One area, though, where research is less positive is in the metabolic effects of cannabinoid receptor activation. Activation of the endocannabinoid regulatory system, an effect of THC and human endogenous cannabinoids anandamide and 2-AG, seemed to correlate with some health-negative metabolic conditions. Conversely, blockage of this activation with synthetic cannabinoid antagonists (e.g. rimonabant) correlated with health positive cardio-metabolic changes. As listed by the European RIO study, some positive changes induced by blocking CB1 receptors include positive changes in body weight, waist circumference, HDL cholesterol, triglycerides, adiponectin, fasting insulin and insulin resistance.

Because of these effects on the endocannabinoid system, it has long been assumed that cannabis consumption would tend to cause weight gain. These metabolic effects and enhanced eating because of amplified taste, i.e. “munchie effects” would theoretically make marijuana users ravenous and fat. To the surprise of many, several studies have now found that cannabis users are actually less fat than their abstaining counterparts. As reported here, marijuana users tend to be less obese and less diabetic than non-users.  Their waists were smaller. These real life observations seem to contradict the supposed munchie effect and predicted effects of CB1 activation. Such health positive indication by cannabis users may even be amplified with development of THCV-heavy cannabis weight loss products e.g. edibles for appetite suppression.

For some people eating does often follow use of THC-heavy marijuana.  Indeed, important medical uses of cannabis include treatment of the wasting syndrome and lack of appetite from chemotherapy. But by no means does everyone using cannabis each time become ravenous. Depending on the person, the setting and the cannabis, consuming cannabis is often a prelude to cardiovascular exercise, not gluttonous indolence. As much as taste enjoyment is enhanced by cannabis for some, for others (or for the same people at other times.) the sensory enjoyment of exercise is enhanced. With cannabis, activities like running can hurt less and feels better, even ecstatic. Might a higher THCV-content cannabis both dampen appetite and create an energetic cannabis experience encouraging exercise?

For a short time in 2005 and 2006, it looked this CB1 receptor antagonist, the synthetic cannabinoid rimonabant, might be a powerful anti-obesity drug. Problems arose for this promising weight loss and metabolic drug, though, from its blockage of the endocannabinoid system. Ananadamide and THC are blissful, because they activate this system. Blockage of the system, it seems, is anti-blissful, with feelings of anxiety and depression common. Also worrisome was blockage of the positive health effects of medical cannabis, e.g. glaucoma reduction and pain relief. For example, cannabis is an anti-nausea drug offering immense relief to chemotherapy patients. And indeed, nausea was another of the symptoms bothering those taking this synthetic “anti-marijuana.” Depression and nausea are probably not part of an effective weigh loss program.

After approval in Europe and other countries, rimonabant was rejected by the FDA. It has since lost favor in Europe. An obese world lost a potentially useful weight control product. Could there be other options? As it turns out one of the phyto-cannabinoids from the cannabis plants, THCV, may have potential. Although its interactions with THC, other cannabinoids and the cannabinoid receptor system are complex, recent research found that THCV is a CB1 and CB2 receptor antagonist. Seemingly, this would make for “downer cannabis,” blocking the CB1 receptors that THC activate, but that does not seem to be the case. It is possible THCV intensive cannabis might offer the appetite reduction and  and positive cardiometabolic effects of Rimonabant without the negatives of the synthetic drug. This is especially true when the THCV is mixed, with other cannabinoids, as found in cannabis. A cannabis with high THCV and low or moderate THC and CBD might be ideal.

Seminal cannabis researcher and discoverer of THC, Raphael Mechoulam, in British Journal of Pharmacology in 2005, discussed the apparent unique properties and posed several research questions. He notes, as has Scottish researcher Roger G. Pertwee, that THCV content can be very high in hashish from Pakistan. Despite these high levels of the supposed CB1 receptor antagonist THCV, Pakistani hashish has no apparent  “downer” aspect depressing the user. Perhaps this is due to the presence of the other 60 cannabinoids.

THCV’s appetite-reducing and fat loss potential await studies, as do new cannabis cultivars enhancing this cannabinoid. Except, of course, no studies on the medical potential of cannabis are allowed in the USA by the DEA.  Americans, so in need of useful weight loss products, will have to wait until the research is done in places like Israel, Spain and Portugal.

Copyright © 2013 Don Fitch

Protecting the brain with cannabinoid receptor activation.

Cannabinoid receptors, small protein structures in the cell walls of neurons (and other cells) have been shown positive effects in protecting the brain from degeneration. Now, new research out of Bonn, Germany confirms how important CB1 receptors and the activation of these receptors, are to the well-being of our aging brains. Science Daily‘s write up of the research was entitled, Bodyguard for the Brain: Researchers Identify Mechanism That Seems to Protect Brain from Aging. The bodyguard mentioned is none other than the CB1 receptor, which is activated by endocannabinoids such as anandamide and also by the plant cannabinoid, THC.  Activation of the CB1 receptors helped protect the brain from inflammation, memory loss, and learning deficiency. It prevented nerve cell loss in the critical hippocampus structure. These were mouse studies but with strong correlation to human learning, aging, memory and dementia.

Seemingly, this research would have important implications for medical cannabis. One of the main effects of  cannabis and its cannabinoids such as THC is the activation of these CB receptors in the brain. This research would imply that such activation provides a neuroprotective, anti-aging effect.

Another implication would include caution towards the use of CB1 receptor antagonists and/or CB1 receptor inverse agonist. Rimonabant, is just such a compound, acting as a blocker and perhaps inverse activator of CB1 receptors. Five years ago there was great hope that this “anti-marijuana” would make an effective weight loss drug, by causing the “anti-munchies.” But just as cannabis provides a mild uplifting “high,” this drug predictably caused the opposite effect, that is depression. It failed approval by the FDA and was later removed in some European markets for its depressive (and sometimes nauseating) effects. The new German research should spur caution about the possible brain degenerative effects of blocking CB receptors.

Regarding the importance of the identification of the CB1 receptor in brain neuroprotection, one of the lead German researchers noted: “The root cause of aging is one of the secrets of life. This study has begun to open the door to solving this enigma.”

Parkinson’s Disease and the THCV in cannabis.

New British and Spanish research on one of cannabis’ cannabinoids show its great potential for treating Parkinson’s disease. The cannabinoid is the lesser known but hugely interesting THCV, aka Delta-9-tetrahydrocannabivarin. The molecule is present to varying decrees in different strains of cannabis, from trace amounts to a hefty proportion.

Unlike your own body’s cannabinoid anandamide, or its phyto(plant based)-cannabinoid cousin, THC, THCV does not activate CB1 receptors in your endocannbinoid regulatory system. Activation of these CB1 receptors, found mainly on nerve cells, is responsible for most of THC’s psychoactive effects and medical benefits. THC also activates CB2 receptors, found more on immune cells and thought responsible for some of cannabis’ beneficial effects on some autoimmune disorders. Like THC, THCV also binds with and activates these CB2 receptors. Like THC, THCV is a powerful antioxidant, capable of sopping up cell-killing free radicals. Unlike THC, THCV does not activate CB1 receptors. Instead, it blocks (serves as an antagonist to) the activation of the CB1 system. It may play a major role in future treatments of cardiometabolic diseases and obesity.

The International Association of Cannabinoid Medicine reported the research as follows:

Parkinson’s disease
Spanish and British researchers investigated the effects of Delta-9-
tetrahydrocannabivarin (THCV) in an animal model of Parkinson’s
disease
. They concluded that “given its antioxidant properties and
its ability to activate CB2 but to block CB1 receptors, Delta-9-THCV
has a promising pharmacological profile for delaying disease
progression in PD and also for ameliorating parkinsonian symptoms.”
(Source: García C, et al. Br J Pharmacol. 2011 Feb 16. [in press]).

The fact that the research was British and Spanish, not American, is telling. Americans are not allowed to research cannabis and are denied access to marijuana for research. The pathetic paucity of medical cannabis research in the USA is a literal crime against humanity, a function of politics of prohibition. Americans by the millions suffer untreated pain, blinding glaucoma and immobilizing Parkinson’s disease while all research is denied, decade after decade. Instead of following a science-based assessment (which would demand a rush to research medical cannabis), American science has been held hostage to authoritarian bureaucrats.